sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer

Inclusion Criteria: * Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information * NOTE: HIPAA authorization may be included in the informed consent or obtained separately * Eastern Cooperative Oncology Group (ECOG) performance status of =\< 1 within 14 days prior to being registered for protocol therapy * Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 4 weeks after treatment discontinuation * Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy * NOTE: Subjects are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal * Females must not be breastfeeding * Cohort A - T2, Transitional cell carcinoma (TCC) muscle invasive bladder cancer, (patients who are cisplatin ineligible, decline neoadjuvant and/or ineligible for neoadjuvant chemotherapy); must have histological proof of T2, muscle-invasive transitional cell carcinoma of the bladder with no evidence of metastatic; patient with any degree of fixation of the pelvic sidewall are not eligible * Cohort B - Prostate cancer (Gleason 7 or less); must have histological proof of Gleason =\< 7 with no evidence of metastatic disease (patient with any degree of extra-prostatic capsule extension are not eligible * Cohort C - Renal cell carcinoma (\> pT1b); must have radiologic suspicion or histological proof of clear cell renal cell carcinoma \>= 4 cm with no evidence of metastatic disease; patient with any degree of tumor extension into the renal vein are not eligible; patients must be candidates for contrast-enhanced ultrasound (CEUS) imaging and agree to undergo this additional imaging technique * Patients must be willing to undergo a biopsy of the cancerous tissue if one was not taken within the previous year, prior to drug initiation if tumor block is not available; biopsy must be done within 14 days of first planned drug dose * Patients must be willing to undergo a radiologic scan (computed tomography \[CT\] or magnetic resonance imaging \[MRI\], depending on organ involved) after last drug dose and prior to minimally-invasive surgery * Eligible for: * Cohort A: Robot-assisted radical cystectomy (RARC) as per the attending urologist * Cohort B: Robot-assisted radical Nephrectomy (RARN)/robot-assisted partial nephrectomy (RAPN) as per the attending urologist * Cohort C: RAPN as per the attending urologist * No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancers for which the patient has been disease-free for at least 5 years * No treatment with any investigational agent within 30 days prior to being registered for protocol therapy * No prior systemic chemotherapy for transitional cell carcinoma of the bladder (prior intravesical therapy is allowed); any other prior chemotherapy must have been completed \> 5 years prior to initiation of therapy * Prior radiation therapy is allowed provided that no radiation therapy was administered to the urinary bladder * NOTE: No radiation therapy within 28 days prior to being registered for protocol therapy; laboratory values must be obtained within 14 days prior to being registered for protocol therapy * Total bilirubin \< 2.0 X upper limit of normal (ULN) * Aspartate aminotransferase (AST) =\< 2.5 X ULN * Alanine aminotransferase (ALT) =\< 2.5 X ULN * Serum Creatinine \< 2.5 X ULN * Absolute neutrophil count (ANC) \> 1.5 X K/mm\^3 * Platelets \> 100 K/mm\^3 * International normalized ratio (INR) =\< 1.2 * There are currently no known concomitant medications that must be discontinued prior to administration of registration on study and for the duration of sEphB4-HSA * No clinically significant infections as judged by the treating investigator * No pleural or pericardial effusion of any grade * No uncontrolled angina, congestive heart failure or myocardial infraction (MI) within 6 months prior to registration on study * No diagnosed arrhythmias * No abnormalities on pre-entry electrocardiogram, obtained within 28 days prior to being registered on study * No history of diagnosed congenital bleeding disorders (e.g., von Willebrand's disease) * No abnormalities no history of diagnosed acquired bleeding disorders within one year (e.g., acquired anti-factor VIII antibodies) of registration on protocol therapy * No abnormalities no history of ongoing or recent (less than or equal to 3 months of registration on protocol therapy) significant gastrointestinal bleeding * No ongoing anti-coagulation and/or anti-platelet therapies allowed * Patients with diagnosed uncontrolled hypertension (\> 150/90 mmHg) are to be excluded * Patients with hypertension controlled with medications are allowed * No evidence of gross hematuria * No evidence of hydronephrosis * No evidence of a history of a stroke or myocardial infarction within the last 6 months prior to study enrollment * No evidence of a history of wound healing complications prior to study enrollment